Keywords
How to Cite
Abstract
In patients with hypertension, target organ damage, including left ventricular hypertrophy and increased arterial stiffness, worsens the prognosis. A study involving 52 patients evaluated the effect of 6 months of therapy with the fixed-dose combination of telmisartan/amlodipine. A significant reduction in left ventricular myocardial mass index (by 7.6%), central arterial pressure, and pulse wave velocity was found. These data indicate a pronounced cardioprotective and vasoprotective effect of the therapy, which may contribute to an improved long-term prognosis in patients with hypertension.
References
1. World Health Organization. Global report on hypertension: the race against a silent killer. Geneva: WHO; 2023.
2. European Society of Cardiology, European Society of Hypertension. 2023 ESC/ESH Guidelines for the management of arterial hypertension. European Heart Journal. 2023;44(21):180–276.
3. Bryan Williams, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. European Heart Journal. 2018;39(33):3021–3104.
4. Giuseppe Mancia, et al. Reappraisal of European guidelines on hypertension management. Journal of Hypertension. 2009;27(11):2121–2158.
5. Michael E. Safar, Alberto P. Avolio. Arterial stiffness and cardiovascular risk: implications for therapy. Hypertension. 2007;50(1):e5–e7.